Estimating the Time to Benefit for Therapies in Heart Failure with Reduced Ejection Fraction: A Case Study of Sacubitril-Valsartan Using Reconstructed Data from a Randomized Controlled Trial.
Lorenz Roger Van der LindenJulie HiasKarolien WalgraeveJos TournoyLucas Van AelstChristophe VandenbrielePublished in: Drugs & aging (2022)
Using multiple approaches, the earliest benefit of sacubitril-valsartan compared to enalapril in stable HFrEF was found at about 1 month after initiation.